Life Sciences Products & Reviews

Custom DNA/RNA oligonucleotide synthesis with broad modification choices (PS, 2′-OMe, 2′-F, LNA, GalNAc, dyes/biotin), multiple scales and purifications, and analytical QC. Includes design consultation and documentation to support research, translational studies, and conjugation-ready formats.

Recombinant Human Antibody (D25) is capable of binding to RSV, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-RSV mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-RSV mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.

The antibody specifically targets the CD3 epsilon chain present on T lymphocytes. It binds to the CD3 molecule on the surface of T cells. By engaging with CD3, the mAb alters the immune response, offering potential in decelerating the progression of type 1 diabetes.

Integrated ASO development from sequence design and chemistry selection to preclinical PK/PD, safety, delivery (e.g., GalNAc), and CMC—supporting gapmer and steric-blocker approaches to advance programs efficiently toward IND.

Microelectrode arrays (MEAs) are a valuable tool for recording and measuring neuronal activity. This technology allows us to evaluate in real time how neuronal activity behaves in an environmentally controlled environment. In addition to spontaneous neuronal activity, electrical or compound stimulation can be performed, and over 40 different parameters are recorded simultaneously.

This product is a human monoclonal IgG1 kappan antibody targeting the Gnl domain of glycoprotein N (Gn) of severe fever with thrombocytopenia syndrome virus (SFTSV). This antibody shows the ability to neutralize SFTSV broadly, using the antibody neutralization of the SFTSV, which makes the antibody a specific drug and so clinically useful in preventing SFTSV through the treatment studies of diseases caused by infection.

Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. Bevacizumab is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).

Recombinant monoclonal antibody to IL5RA. It is a monoclonal antibody for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).

Recombinant Mouse Antibody (M75) is capable of binding to CA9. The adhesion site of CA IX appears to overlap with the PGEEDLP epitope of the monoclonal antibody M75, since the antibody blocks attachment of cells to immobilized CA IX protein.

Recombinant monoclonal antibody to CD274. This antibody is a human IgG1 monoclonal antibody that targets and binds to PD-L1, a protein that is often overexpressed on the surface of cancer cells and immune cells in the tumor microenvironment.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Creative Biolabs' stem cell platform offers world-class expertise in the generation, differentiation, and gene-editing of iPSCs and uses this to provide solutions for your drug research and development needs.

Recombinant monoclonal antibody to Human IL5. It is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5) and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma that represents less than 5% of all asthma.

Creative Biolabs specializes in the discovery of single domain antibodies (sdAbs) with high affinity and specificity.

Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1, and HER1 in humans).

This product is a recombinant Human antibody that recognizes MS4A1/CD20. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.

This product is a recombinant Mouse antibody that recognizes DOTA. The antibody was expressed in mammalian cells with chemically defined culture media and was purified by affinity chromatography.

Comprehensive circRNA services including design, circularization (e.g., ribozyme/intron-mediated), purification, and analytics to deliver stable, translation-competent RNA with improved durability—supported by process development for research and translational programs.

Recombinant Rabbit Antibody is capable of binding to Hypusine, expressed in Chinese Hamster Ovary cells (CHO).

Recombinant Human Antibody (B20-4) is capable of binding to VEGF, expressed in HEK293 cells. Expressed as the combination of a heavy chain (HC) containing VH from antiVEGF mAb and the CH1-3 region of human IgG1 and a light chain (LC) encoding VL from antiVEGF mAb and CL of human kappa light chain. Exists as a disulfide-linked dimer of the HC and LC heterodimer under non-reducing conditions.

End-to-end viral vector design and construction covering vector/serotype selection, expression-cassette optimization, cloning, packaging, purification, and QC. Supports AAV, lentivirus, adenovirus, HSV, vaccinia, and baculovirus with scalable production and documentation for in vitro/in vivo studies and IND-enabling work.

The NucleoCounter® SP-100™ sperm cell counter offers unique ease of use and effective determination of total sperm concentration and viability in semen samples from ejaculates or extended doses. The NucleoCounter® SP-100™ is very simple to operate and the measurements can be performed by operators with only limited training in laboratory work.

Disruptive technology for the characterization of small molecules and fragments. With enhanced sensitivity, expanded thermal options, and advanced microfluidics, the Carterra Ultra™ platform is our most sensitive instrument for interrogating multiple proteins and off-target binding in parallel.

Disruptive Technology for Screening and Characterization. Enhanced sensitivity and fast data collection rate build upon unmatched capabilities in throughput and enable assays such as TPDs/PROTAC®s, kinase, cytokines, DELs, and protein:protein inhibitors.

Disruptive Technology for mAb Screening and Characterization.